JAGX vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JAGX exhibits extreme financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.13, indicating negative shareholder equity. The company is facing a severe liquidity crisis with a Quick Ratio of 0.07, suggesting it cannot meet short-term obligations. Despite a positive gross margin, the operating margin is catastrophic at -631.90%, and the stock has collapsed by 92.8% over the last year. The combination of declining revenue and consistent earnings misses points toward a high risk of insolvency.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
JAGX vs LLY: Head-to-Head Comparison
This page compares Jaguar Health, Inc. (JAGX) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.